Abliva

Focus: Abliva is a Swedish biotech company with 1,001-5,000 employees focused on small molecule development for rare and orphan diseases. The company operates from Lund and maintains a clinical-stage pipeline targeting high-unmet-need indications.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Employees

1001-5000

Open Jobs

About Abliva

AI assessmentNot Hiring

No open roles listed right now. Follow Abliva to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

cyclosporine

Traumatic Brain Injury

Phase 2

Clinical Trials (1)

NCT01692834A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers

Phase 1

Help build intelligence for Abliva

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to Phase 2 programs in high-impact areas like mitochondrial disease and traumatic brain injury with significant unmet medical need
Mid-sized organization (1,001-5,000 employees) offers broader career visibility than megacorps while maintaining biotech agility
European headquarters provides alternative career pathway to US-centric pharma structure

Watch Out For

No active job openings currently listed, suggesting limited near-term hiring momentum or potential restructuring pause
Early-stage pipeline (Phase 2 maximum, zero Phase 3 programs) means extended timeline to clinical validation and revenue generation
Missing critical financial data (revenues, R&D spend, cash position) raises transparency concerns about company stability and growth trajectory

Generated by Claude from Abliva's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NeuroSTAT 5 mg/kg/day

Traumatic Brain Injury

Phase 2

Clinical Trials (1)

NCT01825044Copenhagen Head Injury Ciclosporin (CHIC) Study

Phase 2

KL1333

Primary Mitochondrial Disease

Phase 2

Clinical Trials (3)

NCT05650229Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

Phase 2

NCT03888716A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

Phase 1

NCT04643249Drug-drug Interaction Study of KL1333 in Healthy Subjects

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Respiratory

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Respiratory

1 pipeline

Marketed

Pipeline